Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 209, 10.3322/caac.21660 Cao, 2021, Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020, Chin. Med. J. (Engl.), 134, 783, 10.1097/CM9.0000000000001474 Qiu, 2021, Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020, Cancer Commun. (Lond), 41, 1037, 10.1002/cac2.12197 Janjigian, 2021, First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial, Lancet, 398, 27, 10.1016/S0140-6736(21)00797-2 Van Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group, J. Clin. Oncol., 24, 4991, 10.1200/JCO.2006.06.8429 Shitara, 2017, Chemotherapy for advanced gastric cancer: Future perspective in Japan, Gastric Cancer, 20, 102, 10.1007/s10120-016-0648-7 Pavel, 2020, Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 31, 844, 10.1016/j.annonc.2020.03.304 Shen, 2022, Anticancer drug R&D of gastrointestinal cancer in China: Current landscape and challenges, Innovation (Camb), 3 Tsukita, 2001, Multifunctional strands in tight junctions, Nat. Rev. Mol. Cell Biol., 2, 285, 10.1038/35067088 Günzel, 2013, Claudins and the modulation of tight junction permeability, Physiol. Rev., 93, 525, 10.1152/physrev.00019.2012 Otani, 2020, Tight junction structure and function revisited, Trends Cell Biol., 30, 805, 10.1016/j.tcb.2020.08.004 Tabariès, 2017, The role of claudins in cancer metastasis, Oncogene, 36, 1176, 10.1038/onc.2016.289 Hashimoto, 2022, Claudins and gastric cancer: An overview, Cancers (Basel), 14, 290, 10.3390/cancers14020290 Sahin, 2021, FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma, Ann. Oncol., 32, 609, 10.1016/j.annonc.2021.02.005 Gong, 2022 Qi, 2022, Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results, Nat. Med., 28, 1189, 10.1038/s41591-022-01800-8 Fan, 2021, Ultrasensitive gastric cancer circulating tumor cellular CLDN18.2 RNA detection based on a molecular beacon, Anal. Chem., 93, 665, 10.1021/acs.analchem.0c04055 Gu, 2022, Relationship of 18F-FDG PET/CT parameters and CLDN 18.2 expression status in gastric cancer, J. Nucl. Med., 63 Hu, 2022, Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: A preclinical study, Eur. J. Nucl. Med. Mol. Imaging, 49, 2634, 10.1007/s00259-022-05739-3 Hu, 2022, Study of 89Zr-labeled recombinant antibody VHH-Fc for noninvasive evaluation of CLDN18.2 expression in gastric cancer, J. Nucl. Med., 63, 2525 Zhao, 2022, Targeting Claudin 18.2 using a highly specific antibody enables cancer diagnosis and guided surgery, Mol. Pharm., 19, 3530, 10.1021/acs.molpharmaceut.1c00947 Börjesson, 2009, Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients, J. Nucl. Med., 50, 1828, 10.2967/jnumed.109.065862 Laforest, 2016, [89Zr]Trastuzumab: Evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer, Mol. Imaging Biol., 18, 952, 10.1007/s11307-016-0951-z O'Donoghue, 2018, Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-Trastuzumab in patients with esophagogastric cancer, J. Nucl. Med., 59, 161, 10.2967/jnumed.117.194555 England, 2017, Preclinical pharmacokinetics and biodistribution studies of 89Zr-Labeled pembrolizumab, J. Nucl. Med., 58, 162, 10.2967/jnumed.116.177857 Sobol, 2021, Immuno-PET imaging of pancreatic tumors with 89Zr-Labeled gold nanoparticle-antibody conjugates, Mol. Imag. Biol., 23, 84, 10.1007/s11307-020-01535-3 Vivier, 2019, The impact of FcγRI binding on immuno-PET, J. Nucl. Med., 60, 1174, 10.2967/jnumed.118.223636 Adumeau, 2022, Site-specific, platform-based conjugation strategy for the synthesis of dual-labeled immunoconjugates for bimodal PET/NIRF imaging of HER2-positive tumors, Bioconjug. Chem., 33, 530, 10.1021/acs.bioconjchem.2c00049 Lamberts, 2015, Antibody positron emission tomography imaging in anticancer drug development, J. Clin. Oncol., 33, 1491, 10.1200/JCO.2014.57.8278 Zhang, 2020, Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer, Chin. J. Cancer Res., 32, 263, 10.21147/j.issn.1000-9604.2020.02.13